Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance and pharmacokinetics study of radiolabeled BCX7353 in healthy male subjects
NL-OMON44289Phase 1Active, not recruiting
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of berotralstat in hereditary angioedema (HAE), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Mass balance of [14C]-BCX7353. Started Sep 2017; status: active, not recruiting.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON44289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44289.